CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically
During recent discussions with the FDA, the agency suggested that developing leronlimab for critically ill COVID-19 patients in current situation in U.S. appears feasibleVANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing lero...
Source: pharmiweb.com